214 related articles for article (PubMed ID: 15735038)
21. Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer.
Younes MN; Kim S; Yigitbasi OG; Mandal M; Jasser SA; Dakak Yazici Y; Schiff BA; El-Naggar A; Bekele BN; Mills GB; Myers JN
Mol Cancer Ther; 2005 Aug; 4(8):1146-56. PubMed ID: 16093430
[TBL] [Abstract][Full Text] [Related]
22. Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer.
Awasthi N; Kronenberger D; Stefaniak A; Hassan MS; von Holzen U; Schwarz MA; Schwarz RE
Cancer Lett; 2019 Sep; 459():41-49. PubMed ID: 31153980
[TBL] [Abstract][Full Text] [Related]
23. Glaucarubinone and gemcitabine synergistically reduce pancreatic cancer growth via down-regulation of P21-activated kinases.
Yeo D; Huynh N; Beutler JA; Christophi C; Shulkes A; Baldwin GS; Nikfarjam M; He H
Cancer Lett; 2014 May; 346(2):264-72. PubMed ID: 24491405
[TBL] [Abstract][Full Text] [Related]
24. Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival.
Troussard AA; McDonald PC; Wederell ED; Mawji NM; Filipenko NR; Gelmon KA; Kucab JE; Dunn SE; Emerman JT; Bally MB; Dedhar S
Cancer Res; 2006 Jan; 66(1):393-403. PubMed ID: 16397254
[TBL] [Abstract][Full Text] [Related]
25. BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer.
Awasthi N; Zhang C; Ruan W; Schwarz MA; Schwarz RE
Mol Cancer Ther; 2012 Dec; 11(12):2644-53. PubMed ID: 23047891
[TBL] [Abstract][Full Text] [Related]
26. Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma.
Koul D; Shen R; Bergh S; Lu Y; de Groot JF; Liu TJ; Mills GB; Yung WK
Mol Cancer Ther; 2005 Nov; 4(11):1681-8. PubMed ID: 16275989
[TBL] [Abstract][Full Text] [Related]
27. Integrin-linked kinase (ILK): a "hot" therapeutic target.
Yoganathan TN; Costello P; Chen X; Jabali M; Yan J; Leung D; Zhang Z; Yee A; Dedhar S; Sanghera J
Biochem Pharmacol; 2000 Oct; 60(8):1115-9. PubMed ID: 11007949
[TBL] [Abstract][Full Text] [Related]
28. Effect of Z-360, a novel orally active CCK-2/gastrin receptor antagonist on tumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action determinations in vitro.
Kawasaki D; Emori Y; Eta R; Iino Y; Hamano H; Yoshinaga K; Tanaka T; Takei M; Watson SA
Cancer Chemother Pharmacol; 2008 Apr; 61(5):883-92. PubMed ID: 17901954
[TBL] [Abstract][Full Text] [Related]
29. Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts.
Cao P; Maira SM; García-Echeverría C; Hedley DW
Br J Cancer; 2009 Apr; 100(8):1267-76. PubMed ID: 19319133
[TBL] [Abstract][Full Text] [Related]
30. Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models.
Chang Q; Chen E; Hedley DW
Cancer Biol Ther; 2009 Oct; 8(20):1893-901. PubMed ID: 20009539
[TBL] [Abstract][Full Text] [Related]
31. Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer.
Venkannagari S; Fiskus W; Peth K; Atadja P; Hidalgo M; Maitra A; Bhalla KN
Oncotarget; 2012 Nov; 3(11):1416-27. PubMed ID: 23232026
[TBL] [Abstract][Full Text] [Related]
32. Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.
Sloss CM; Wang F; Liu R; Xia L; Houston M; Ljungman D; Palladino MA; Cusack JC
Clin Cancer Res; 2008 Aug; 14(16):5116-23. PubMed ID: 18698029
[TBL] [Abstract][Full Text] [Related]
33. In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer.
Ito D; Fujimoto K; Mori T; Kami K; Koizumi M; Toyoda E; Kawaguchi Y; Doi R
Int J Cancer; 2006 May; 118(9):2337-43. PubMed ID: 16331623
[TBL] [Abstract][Full Text] [Related]
34. Ursolic acid inhibits growth and induces apoptosis in gemcitabine-resistant human pancreatic cancer via the JNK and PI3K/Akt/NF-κB pathways.
Li J; Liang X; Yang X
Oncol Rep; 2012 Aug; 28(2):501-10. PubMed ID: 22641480
[TBL] [Abstract][Full Text] [Related]
35. HS-104, a PI3K inhibitor, enhances the anticancer efficacy of gemcitabine in pancreatic cancer.
Jung KH; Yan HH; Fang Z; Son MK; Lee H; Hong S; Hong SS
Int J Oncol; 2014 Jul; 45(1):311-21. PubMed ID: 24819705
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.
Xu D; Cobb MG; Gavilano L; Witherspoon SM; Williams D; White CD; Taverna P; Bednarski BK; Kim HJ; Baldwin AS; Baines AT
Cancer Biol Ther; 2013 Jun; 14(6):492-501. PubMed ID: 23760491
[TBL] [Abstract][Full Text] [Related]
37. Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine.
Shimasaki T; Ishigaki Y; Nakamura Y; Takata T; Nakaya N; Nakajima H; Sato I; Zhao X; Kitano A; Kawakami K; Tanaka T; Takegami T; Tomosugi N; Minamoto T; Motoo Y
J Gastroenterol; 2012 Mar; 47(3):321-33. PubMed ID: 22041920
[TBL] [Abstract][Full Text] [Related]
38. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
39. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
Nagaraju GP; Mezina A; Shaib WL; Landry J; El-Rayes BF
Eur J Cancer; 2016 Jan; 52():109-19. PubMed ID: 26682870
[TBL] [Abstract][Full Text] [Related]
40. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.
Wu L; Birle DC; Tannock IF
Cancer Res; 2005 Apr; 65(7):2825-31. PubMed ID: 15805283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
